An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors

References

• Stewart BW, Wild C, International Agency for Research on Cancer, World Health Organization. World Cancer Report 2014. Lyon, France & Geneva, Switzerland: International Agency for Research on Cancer, WHO Press, 2014.
   Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376:1164-74; PMID:20888994; https://doi.org/10.1016/S0140-6736(10)61381-5
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; https://doi.org/10.1038/nrc3236
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Hwu P, Drake CG, Camacho LH, Kauh J et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; https://doi.org/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; https://doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33:828-33; PMID:20842054; https://doi.org/10.1097/CJI.0b013e3181eec14c
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; https://doi.org/10.1056/NEJMoa1103849
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-18; PMID:23527958; https://doi.org/10.1056/NEJMoa1215134
   PubMed Web of Science ®Google Scholar
• Suryadevara CM, Gedeon PC, Sanchez-Perez L, Verla T, Alvarez-Breckenridge C, Choi BD, Fecci PE, Sampson JH. Are BiTEs the "missing link" in cancer therapy? Oncoimmunology 2015; 4:e1008339; PMID:26155413; https://doi.org/10.1080/2162402X.2015.1008339
   PubMed Web of Science ®Google Scholar
• Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 2015; 93:290-6; PMID:25367186; https://doi.org/10.1038/icb.2014.93
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-7; PMID:18703743; https://doi.org/10.1126/science.1158545
   PubMed Web of Science ®Google Scholar
• Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol 2016; 34:1104-11; PMID:26884582; https://doi.org/10.1200/JCO.2014.59.1586
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120:5185-7; PMID:23024237; https://doi.org/10.1182/blood-2012-07-441030
   PubMed Web of Science ®Google Scholar
• Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK et al. Analysis of ROR1 protein expression in human cancer and normal tissues. Clin Cancer Res 2016; PMID:27852699; https://doi.org/10.1158/1078-0432
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, Wu R, Kipps TJ. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol 2012; 181:1903-10; PMID:23041612; https://doi.org/10.1016/j.ajpath.2012.08.024
   PubMed Web of Science ®Google Scholar
• Henry CE, Emmanuel C, Lambie N, Loo C, Kan B, Kennedy CJ, de Fazio A, Hacker NF, Ford CE. Distinct patterns of stromal and tumor expression of ROR1 and ROR2 in histological subtypes of epithelial ovarian cancer. Transl Oncol 2017; 10:346-56; PMID:28342318; https://doi.org/10.1016/j.tranon.2017.01.014
   PubMedGoogle Scholar
• Tan H, He Q, Gong G, Wang Y, Li J, Wang J, Zhu D, Wu X. miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer. Int J Oncol 2016; 48:181-90; PMID: 26575700; https://doi.org/10.3892/ijo.2015.3241
   PubMed Web of Science ®Google Scholar
• Zhang H, Qiu J, Ye C, Yang D, Gao L, Su Y, Tang X, Xu N, Zhang D, Xiong L et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep 2014; 4:5811; PMID:25056203; https://doi.org/10.1038/srep05811
   PubMed Web of Science ®Google Scholar
• Li C, Wang S, Xing Z, Lin A, Liang K, Song J, Hu Q, Yao J, Chen Z, Park PK et al. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol 2017; 19:106-19; PMID:28114269; https://doi.org/10.1038/ncb3464
   PubMed Web of Science ®Google Scholar
• Chien HP, Ueng SH, Chen SC, Chang YS, Lin YC, Lo YF, Chang HK, Chuang WY, Huang YT, Cheung YC et al. Expression of ROR1 has prognostic significance in triple negative breast cancer. Virchows Arch 2016; 468(5):589-95; PMID:26874851; https://doi.org/10.1007/s00428-016-1911-3
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps TJ. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PloS One 2012; 7:e31127; PMID:22403610; https://doi.org/10.1371/journal.pone.0031127
   PubMed Web of Science ®Google Scholar
• Zheng YZ, Ma R, Zhou JK, Guo CL, Wang YS, Li ZG, Liu LX, Peng Y. ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma. Sci Rep 2016; 6:36447; PMID:27830754; https://doi.org/10.1038/srep36447
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang H, Chen T, Luo Y, Xu Z, Li Y, Yang J. Silencing of receptor tyrosine kinase ROR1 inhibits tumor-cell proliferation via PI3K/AKT/mTOR signaling pathway in lung adenocarcinoma. PloS One 2015; 10:e0127092; PMID:25978653; https://doi.org/10.1371/journal.pone.0127092
   PubMed Web of Science ®Google Scholar
• Chang H, Jung WY, Kang Y, Lee H, Kim A, Kim BH. Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma. Ann Diagn Pathol 2015; 19:330-4; PMID:26245996; https://doi.org/10.1016/j.anndiagpath.2015.06.010
   PubMed Web of Science ®Google Scholar
• Fernandez NB, Lorenzo D, Picco ME, Barbero G, Dergan-Dylon LS, Marks MP, García-Rivello H, Gimenez L, Labovsky V, Grumolato L et al. ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K/Akt pathway. Mol Carcinog 2016; 55:1772-85; PMID:26509654; https://doi.org/10.1002/mc.22426
   PubMed Web of Science ®Google Scholar
• O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 2013; 3:1378-93; PMID:24104062; https://doi.org/10.1158/2159-8290.CD-13-0005
   PubMed Web of Science ®Google Scholar
• Potratz J, Tillmanns A, Berning P, Korsching E, Schaefer C, Lechtape B, Schleithoff C, Unland R, Schäfer KL, Müller-Tidow C et al. Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease. Mol Oncol 2016; 10:677-92; PMID:26739507; https://doi.org/10.1016/j.molonc.2015.12.009
   PubMed Web of Science ®Google Scholar
• Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, 2nd, Yu J, Neuberg DS, Wierda WG, Rai KR et al. High-level ROR1 associates with accelerated disease-progression in chronic lymphocytic leukemia. Blood 2016; 128(25):2931-40; PMID:27815263; https://doi.org/10.1182/blood-2016-04-712562
   PubMed Web of Science ®Google Scholar
• Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, Akhondi M, Lagercrantz S, Larsson C, Osterborg A et al. ROR1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 2008; 123:1190-5; PMID:18546292; https://doi.org/10.1002/ijc.23587
   PubMed Web of Science ®Google Scholar
• Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, Staudt LM, Wilson WH, Wiestner A, Rader C. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008; 14:396-404; PMID:18223214; https://doi.org/10.1158/1078-0432.CCR-07-1823
   PubMed Web of Science ®Google Scholar
• Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, Widhopf GF 2nd, Rassenti LZ, Cantwell MJ, Prussak CE et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Nat Acad Sci U S A 2008; 105:3047-52; PMID:18287027; https://doi.org/10.1073/pnas.0712148105
   PubMed Web of Science ®Google Scholar
• Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Klisovic R, Phelps MA, Chen CS et al. ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo. Exp Hematol 2015; 43:770-4. e2; PMID:25937048; https://doi.org/10.1016/j.exphem.2015.04.008
   PubMed Web of Science ®Google Scholar
• Barna G, Mihalik R, Timar B, Tombol J, Csende Z, Sebestyen A, Bödör C, Csernus B, Reiniger L, Peták I et al. ROR1 expression is not a unique marker of CLL. Hematol Oncol 2011; 29:17-21; PMID:20597086; https://doi.org/10.1002/hon.948
   PubMed Web of Science ®Google Scholar
• Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012; 22:656-67; PMID:23153538; https://doi.org/10.1016/j.ccr.2012.08.027
   PubMed Web of Science ®Google Scholar
• Dave H, Anver MR, Butcher DO, Brown P, Khan J, Wayne AS, Baskar S, Rader C. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PloS One 2012; 7:e52655; PMID:23285131; https://doi.org/10.1371/journal.pone.0052655
   PubMed Web of Science ®Google Scholar
• Jung EH, Lee HN, Han GY, Kim MJ, Kim CW. Targeting ROR1 inhibits the self-renewal and invasive ability of glioblastoma stem cells. Cell Biochem Funct 2016; 34:149-57; PMID:26923195; https://doi.org/10.1002/cbf.3172
   PubMed Web of Science ®Google Scholar
• Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF, 2nd, Zhang Z, Wu CC, Chen L, Wu R et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Nat Acad Sci U S A 2014; 111:17266-71; PMID:25411317; https://doi.org/10.1073/pnas.1419599111
   PubMed Web of Science ®Google Scholar
• Henry C, Llamosas E, Knipprath-Meszaros A, Schoetzau A, Obermann E, Fuenfschilling M, Caduff R, Fink D, Hacker N, Ward R et al. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. Oncotarget 2015; 6:40310-26; PMID:26515598; https://doi.org/10.18632/oncotarget.5643
   PubMed Web of Science ®Google Scholar
• Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, Kosasih PL, Rader C, Riddell SR. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res 2015; 3:206-16; PMID:25355068; https://doi.org/10.1158/2326-6066.CIR-14-0163
   PubMed Web of Science ®Google Scholar
• Choi MY, Widhopf GF, 2nd, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C et al. Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1. Clin Lymphoma Myeloma Leuk 2015; 15 Suppl:S167-9; PMID:26297272; https://doi.org/10.1016/j.clml.2015.02.010
   PubMed Web of Science ®Google Scholar
• Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008; 36:W503-8; PMID:18503082; https://doi.org/10.1093/nar/gkn316
   PubMed Web of Science ®Google Scholar
• Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, Clark V, Hristopoulos M, Cook R, Slaga D et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell 2017; 31:383-95; PMID:28262555; https://doi.org/10.1016/j.ccell.2017.02.001
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther 2012; 136:334-42; PMID:22940266; https://doi.org/10.1016/j.pharmthera.2012.07.013
   PubMed Web of Science ®Google Scholar
• Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Trans Med 2015; 7:287ra70; PMID:25972002; https://doi.org/10.1126/scitranslmed.aaa4802
   PubMed Web of Science ®Google Scholar
• Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 2017; PMID:28025583; https://doi.org/10.1038/leu.2016.388
   PubMedGoogle Scholar
• English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E et al. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer 2015; 121:403-12; PMID:25251053; https://doi.org/10.1002/cncr.29062
   PubMed Web of Science ®Google Scholar
• Oberst MD, Fuhrmann S, Mulgrew K, Amann M, Cheng L, Lutterbuese P, Richman L, Coats S, Baeuerle PA, Hammond SA. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs 2014; 6:1571-84; PMID:25484061; https://doi.org/10.4161/19420862.2014.975660
   PubMed Web of Science ®Google Scholar
• Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood 2016; 127:1410-6; PMID:26755709; https://doi.org/10.1182/blood-2015-06-651380
   PubMed Web of Science ®Google Scholar
• Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev 2016; 30:157-67; PMID:26574053; https://doi.org/10.1016/j.blre.2015.10.003
   PubMed Web of Science ®Google Scholar